Trial
NCT05936229
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
Faron Pharmaceuticals Ltd
Condition
Recurrent B Acute Lymphoblastic Leukemia
Intervention
Interferon Beta-1A
Why stopped
Study closed before opening to accrual, no participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-12